Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.93 +0.39 (+0.67%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

44 45 Next >

Will GSK’s Seasonal Strength And Oncology Focus Drive Gains? ↗

January 16, 2025

A look at GSK’s long-term price action reveals critical levels on the monthly chart.

Via Talk Markets

Topics Stocks / Equities

GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference ↗

January 15, 2025

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Via Benzinga

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗

January 14, 2025

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

Via Investor's Business Daily

GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗

January 13, 2025

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Via Benzinga

GSK Enters Agreement to Acquire IDRx, Inc.

January 13, 2025

From GSK plc and IDRx, Inc.

Via Business Wire

Why CureVac (CVAC) Shares Are Volatile ↗

January 10, 2025

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu.

Via Benzinga

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder ↗

January 08, 2025

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses.

Via Benzinga

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally ↗

January 07, 2025

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses...

Via Benzinga

GSK's Sinus Disease Drug Secures Approval In China ↗

January 03, 2025

China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other eosinophilic conditions.

Via Benzinga

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction ↗

December 23, 2024

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.

Via Benzinga

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗

December 19, 2024

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Via Benzinga

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

From FN Media Group LLC

Via GlobeNewswire

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

From FN Media Group LLC

Via GlobeNewswire

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗

December 18, 2024

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Via Investor's Business Daily

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? ↗

December 17, 2024

AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.

Via Investor's Business Daily

What's Going On Moderna Stock On Monday? ↗

December 16, 2024

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.

Via Benzinga

Topics Lawsuit

Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children ↗

December 13, 2024

Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering...

Via Benzinga

Topics Government

Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination ↗

December 13, 2024

Avian flu continues to spread with cases in cats, horses, and humans. Scientists monitor wildlife infections. Vaccine development may face challenges.

Via Benzinga

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗

December 13, 2024

An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.

Via Benzinga

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing ↗

December 12, 2024

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

Via Benzinga

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex ↗

December 10, 2024

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo.

Via Benzinga

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

December 09, 2024

From GSK plc

Via Business Wire

Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades' ↗

December 09, 2024

On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Oracle is going to report a strong quarter.

Via Benzinga

Bird Flu Found In Raw Milk Leads To Recall In California ↗

November 26, 2024

Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's department of public health.

Via Benzinga

Topics Product Recall

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce ↗

November 26, 2024

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

Via Benzinga

Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines? ↗

November 20, 2024

According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry.

Via Benzinga

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients ↗

November 19, 2024

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Starting at $3.75/week.

Subscribe Today